Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28398548 | 0.98 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL5680437 | 0.82 | ACHE (0.35) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL12446305 | 0.82 | CYP3A4 (0.44) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL150139 | 0.81 | TDP1 (0.69) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL8073956 | 0.78 | CYP3A4 (0.65) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL4146230 | 0.78 | CYP3A4 (0.65) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL5680509 | 0.78 | ACHE (0.33) | — | |
| SCHEMBL13800818 | 0.78 | TDP1 (0.39) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL16094790 | 0.78 | CYP3A4 (0.39) | CYP3A4TDP1ESR1ESR2DRD1 | |
| Lithium SCHEMBL31299878 | 0.74 | TDP1 (0.92) | CYP3A4TDP1ESR1ESR2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103254331-B | Process for producing functionalized polymers | BRIDGESTONE CORP | 2015-01-21 | — | — | CN | claimed |
| CN-104220167-A | Method for converting carbon dioxide and bicarbonates into formic acid derivatives using a cobalt complex as a catalytic system | BAYER TECHNOLOGY SERVICES GMBH | 2014-12-17 | — | — | CN | claimed |
| CN-103635421-A | Method for obtaining hydrogen by catalytic decomposition of formic acid | BAYER TECHNOLOGY SERVICES GMBH | 2014-03-12 | — | — | CN | claimed |
| CN-101367892-B | Method for preparing functionalized polymers | BRIDGESTONE CORP | 2014-01-29 | — | — | CN | claimed |
| CN-103254331-A | Process for producing functionalized polymers | BRIDGESTONE CORP | 2013-08-21 | — | — | CN | claimed |
| CN-101367892-A | Method for preparing functionalized polymers | BRIDGESTONE CORP (JP) | 2009-02-18 | — | — | CN | claimed |
| CN-115433227-A | Multidentate phosphine coordinated copper trihalo tri-type complex, and synthesis method and application thereof | 黑龙江大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-103254331-B | Process for producing functionalized polymers | BRIDGESTONE CORP | 2015-01-21 | — | — | CN | disclosed |
| CN-104220167-A | Method for converting carbon dioxide and bicarbonates into formic acid derivatives using a cobalt complex as a catalytic system | BAYER TECHNOLOGY SERVICES GMBH | 2014-12-17 | — | — | CN | disclosed |
| CN-103635421-A | Method for obtaining hydrogen by catalytic decomposition of formic acid | BAYER TECHNOLOGY SERVICES GMBH | 2014-03-12 | — | — | CN | disclosed |
| CN-101367892-B | Method for preparing functionalized polymers | BRIDGESTONE CORP | 2014-01-29 | — | — | CN | disclosed |
| CN-103254331-A | Process for producing functionalized polymers | BRIDGESTONE CORP | 2013-08-21 | — | — | CN | disclosed |
| CN-101367892-A | Method for preparing functionalized polymers | BRIDGESTONE CORP (JP) | 2009-02-18 | — | — | CN | disclosed |
| EP-1472319-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2004-11-03 | — | — | EP | disclosed |
| US-6717016-B2 | HAVING CHEMICAL SELECTIVITY, ENANTIOSELECTIVITY, CATALYTIC ACTIVITY; FOR USE AS A CATALYST FOR ASYMMETRIC SYNTHESES, ESPECIALLY ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-04-06 | — | — | US | disclosed |
| EP-1334976-A1 | Novel phosphine compound, transition metal complex containing said compound as ligand and asymetric synthesis catalyst containing said complex | Takasago International Corporation (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20030144139-A1 | Novel phosphine compound, transition metal complex containing the same phosphine compound as ligand and asymmetric synthesis catalyst containing the complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-07-31 | — | — | US | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030120067-A1 | Process for producing optically active amide from alpha beta- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | TAKASAGO INTERNATIONAL CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-1279660-A1 | Process for producing an optically active amide from an alpha, beta-unsaturated amide derivative in the presence of a transition metal complex containing a phosphine-phosphorane compound and a transition metal | Takasago International Corporation (JP) | 2003-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144139-A1 | Novel phosphine compound, transition metal complex containing the same phosphine compound as ligand and asymmetric synthesis catalyst containing the complex | PHOSPHO1, MEN1, PDCD1 | CYP3A4 1928/4885TDP1 4744/4885ESR1 2813/4885 |
| US-20030120067-A1 | Process for producing optically active amide from alpha beta- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | PHOSPHO1, NAAA, DEGS1 | CYP3A4 1674/4885TDP1 4638/4885ESR1 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.